查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1585644

生技药品契约製造市场：按产品、平台、治疗领域和业务规模划分 - 2025-2030 年全球预测

Biologics Contract Manufacturing Market by Product (Biosimilar, Insulin, Interferons), Platform (Mammalian, Microbial), Therapeutic Area, Scale of Operation - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年生技药品契约製造市场价值为228.2亿美元，预计到2024年将达到265.3亿美元，复合年增长率为16.74%，到2030年将达到674.4亿美元。

生技药品契约製造包括生技药品。对于希望在无需对专业设施进行大量资本投资的情况下有效扩大生产规模的製药和生物技术公司来说，该行业至关重要。生技药品可应用于多种治疗领域，包括肿瘤学、疫苗和自体免疫疾病，为人类和动物的健康做出贡献。契约製造製造商是重要的合作伙伴，提供细胞培养、发酵、精製和分析测试等领域的专业知识。对生技药品契约製造的需求源于对生技药品的需求不断增长、生物技术的进步以及对生产灵活性的需求以管理成本和产能问题。关键的市场成长要素包括慢性病盛行率上升、个人化医疗的日益采用以及一次性系统和连续製造等製造流程的技术进步。市场机会与服务产品的多样化、新兴市场的扩张以及生物相似药开发的合作有关。然而，严格的监管要求、高昂的初始投资成本以及对高技能技术专业知识的需求等挑战可能会限製成长。此外，潜在的供应链中断和品管问题也带来了额外的障碍。创新领域包括开发先进的细胞和基因治疗製造技术、改进的製程分析技术以及最大限度地减少对环境影响的永续製造流程。由于技术的快速进步和监管环境的变化，市场充满活力。为了充分利用商机，企业应专注于培养策略伙伴关係关係、投资技术升级以及扩大服务组合以涵盖端到端解决方案。全面了解监管要求和强大的品管系统对于应对市场复杂性和实现永续成长至关重要。

主要市场统计
基准年[2023] 228.2亿美元
预测年份 [2024] 265.3亿美元
预测年份 [2030] 674.4亿美元
复合年增长率（%） 16.74%

市场动态：快速发展的生技药品契约製造市场的关键市场洞察

供需的动态交互作用正在改变生技药品契约製造市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 对生物相似药和疫苗生产的需求增加
    • 奇美电子持续投资扩大产能
    • 合约服务的主要好处包括节省成本和时间
  • 市场限制因素
    • 国家间贸易政策的变化
  • 市场机会
    • 一次性生物製程设备和解决方案的出现
    • 标靶治疗的细胞和基因疗法的需求不断增长
  • 市场挑战
    • 对智慧财产权和专利侵权的担忧

波特的五力：驾驭生技药品契约製造市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解生技药品契约製造市场的外部影响

外部宏观环境因素在塑造生技药品契约製造市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解生技药品契约製造市场的竞争状况

生技药品契约製造市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵生技药品契约製造市场供应商的绩效评估

FPNV定位矩阵是评估生技药品契约製造市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划生技药品契约製造市场的成功之路

对于希望加强在全球市场的影响力的公司来说，对生技药品契约製造市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 对生物相似药和疫苗生产的需求增加
      • 奇美电子持续扩大产能投资活动
      • 合约服务的主要好处包括节省成本和时间
    • 抑制因素
      • 国家间贸易政策的变化
    • 机会
      • 推出一次性生物製程设备和解决方案
      • 对标靶治疗的细胞和基因治疗的需求不断增加
    • 任务
      • 对智慧财产权和专利侵权的担忧
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章生技药品契约製造市场：副产品

  • 生物相似药
  • 胰岛素
  • 干扰素
  • 单株抗体
  • 重组激素
  • 疫苗

第七章生技药品契约製造市场：依平台

  • 哺乳动物的
  • 微生物

第八章按治疗领域分類的生技药品契约製造市场

  • 自体免疫疾病
  • 心血管疾病
  • 感染疾病
  • 代谢性疾病
  • 神经病学
  • 肿瘤学
  • 眼科
  • 呼吸系统疾病

第九章按业务规模分類的生技药品契约製造市场

  • 临床
  • 商业的

第十章美洲生技药品契约製造市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太生技药品契约製造市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的生技药品契约製造市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie, Inc.
  • Abzena Ltd.
  • Acino International AG
  • ADMA Biologics, Inc.
  • AGC Biologics
  • Ajinomoto Bio-Pharma Services
  • Avid Bioservices, Inc.
  • Baxter International, Inc
  • Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company
  • Cambrex Corporation
  • Catalent, Inc.
  • Emergent BioSolutions, Inc.
  • FUJIFILM Diosynth Biotechnologies USA, Inc. by FUJIFILM Corporation
  • JSR Life Sciences, LLC by JSR Group
  • Kemwell Biopharma Pvt. Ltd.
  • Lonza Group Ltd.
  • Midas Pharma GmbH
  • ProBioGen AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Thermo Fisher Scientific, Inc.
  • Toyobo Co. Ltd.
  • Wacker Chemie AG
  • WuXi Biologics Co., Ltd.
Product Code: MRR-8C74ADFBFD4E

The Biologics Contract Manufacturing Market was valued at USD 22.82 billion in 2023, expected to reach USD 26.53 billion in 2024, and is projected to grow at a CAGR of 16.74%, to USD 67.44 billion by 2030.

Biologics contract manufacturing encompasses the outsourcing of production processes for biologics-complex molecules such as proteins, nucleic acids, or cells produced through biological processes. This industry is crucial for pharmaceutical and biotech companies seeking to scale production efficiently without significant capital investment in specialized facilities. The application of biologics spans various therapeutic areas, including oncology, vaccines, and autoimmune diseases, catering to both human and veterinary health. Contract manufacturers serve as key partners, offering expertise in areas such as cell culture, fermentation, purification, and analytical testing. The necessity for biologics contract manufacturing arises from the growing demand for biologics, advancements in biotechnology, and the need for flexibility in production to manage costs and capacity issues. Key market growth factors include the rising prevalence of chronic diseases, increasing adoption of personalized medicine, and technological advancements in manufacturing processes, such as single-use systems and continuous manufacturing. Opportunities in the market are tied to the diversification of service offerings, expansion in emerging markets, and collaboration on biosimilar development. However, challenges such as stringent regulatory requirements, high initial investment costs, and the need for highly skilled technical expertise can restrain growth. Furthermore, potential supply chain disruptions and quality control issues present additional hurdles. Innovation areas include the development of advanced cell and gene therapy manufacturing techniques, improvements in process analytical technologies, and sustainable manufacturing processes to minimize environmental impact. The market is dynamic, driven by rapid technological advancements and shifting regulatory landscapes. To capitalize on opportunities, companies should focus on fostering strategic partnerships, investing in technology upgrades, and expanding service portfolios to cover end-to-end solutions. A comprehensive understanding of regulatory requirements and a robust quality management system are crucial to navigating market complexities and achieving sustainable growth.

KEY MARKET STATISTICS
Base Year [2023] USD 22.82 billion
Estimated Year [2024] USD 26.53 billion
Forecast Year [2030] USD 67.44 billion
CAGR (%) 16.74%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biologics Contract Manufacturing Market

The Biologics Contract Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing demand for biosimilars and vaccine production
    • Ongoing investment activities by CMOs for capacity expansion
    • Key advantages such as cost and time saving offered by contract services
  • Market Restraints
    • Changing trade policies between countries
  • Market Opportunities
    • Emergence of single-use bioprocessing equipment & solutions
    • Rising demand for cell and gene therapies for targeted treatment
  • Market Challenges
    • Concerns over the breach of intellectual property and patents

Porter's Five Forces: A Strategic Tool for Navigating the Biologics Contract Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biologics Contract Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biologics Contract Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biologics Contract Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biologics Contract Manufacturing Market

A detailed market share analysis in the Biologics Contract Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biologics Contract Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biologics Contract Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biologics Contract Manufacturing Market

A strategic analysis of the Biologics Contract Manufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biologics Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Abzena Ltd., Acino International AG, ADMA Biologics, Inc., AGC Biologics, Ajinomoto Bio-Pharma Services, Avid Bioservices, Inc., Baxter International, Inc, Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company, Cambrex Corporation, Catalent, Inc., Emergent BioSolutions, Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation, JSR Life Sciences, LLC by JSR Group, Kemwell Biopharma Pvt. Ltd., Lonza Group Ltd., Midas Pharma GmbH, ProBioGen AG, Recipharm AB, Rentschler Biopharma SE, Samsung Biologics, Thermo Fisher Scientific, Inc., Toyobo Co. Ltd., Wacker Chemie AG, and WuXi Biologics Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Biologics Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Biosimilar, Insulin, Interferons, Monoclonal Antibodies, Recombinant Hormones, and Vaccines.
  • Based on Platform, market is studied across Mammalian and Microbial.
  • Based on Therapeutic Area, market is studied across Autoimmune Diseases, Cardiovascular Diseases, Infectious Diseases, Metabolic Diseases, Neurology, Oncology, Ophthalmology, and Respiratory Disorders.
  • Based on Scale of Operation, market is studied across Clinical and Commercial.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing demand for biosimilars and vaccine production
      • 5.1.1.2. Ongoing investment activities by CMOs for capacity expansion
      • 5.1.1.3. Key advantages such as cost and time saving offered by contract services
    • 5.1.2. Restraints
      • 5.1.2.1. Changing trade policies between countries
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of single-use bioprocessing equipment & solutions
      • 5.1.3.2. Rising demand for cell and gene therapies for targeted treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns over the breach of intellectual property and patents
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biologics Contract Manufacturing Market, by Product

  • 6.1. Introduction
  • 6.2. Biosimilar
  • 6.3. Insulin
  • 6.4. Interferons
  • 6.5. Monoclonal Antibodies
  • 6.6. Recombinant Hormones
  • 6.7. Vaccines

7. Biologics Contract Manufacturing Market, by Platform

  • 7.1. Introduction
  • 7.2. Mammalian
  • 7.3. Microbial

8. Biologics Contract Manufacturing Market, by Therapeutic Area

  • 8.1. Introduction
  • 8.2. Autoimmune Diseases
  • 8.3. Cardiovascular Diseases
  • 8.4. Infectious Diseases
  • 8.5. Metabolic Diseases
  • 8.6. Neurology
  • 8.7. Oncology
  • 8.8. Ophthalmology
  • 8.9. Respiratory Disorders

9. Biologics Contract Manufacturing Market, by Scale of Operation

  • 9.1. Introduction
  • 9.2. Clinical
  • 9.3. Commercial

10. Americas Biologics Contract Manufacturing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Biologics Contract Manufacturing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Biologics Contract Manufacturing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie, Inc.
  • 2. Abzena Ltd.
  • 3. Acino International AG
  • 4. ADMA Biologics, Inc.
  • 5. AGC Biologics
  • 6. Ajinomoto Bio-Pharma Services
  • 7. Avid Bioservices, Inc.
  • 8. Baxter International, Inc
  • 9. Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company
  • 10. Cambrex Corporation
  • 11. Catalent, Inc.
  • 12. Emergent BioSolutions, Inc.
  • 13. FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
  • 14. JSR Life Sciences, LLC by JSR Group
  • 15. Kemwell Biopharma Pvt. Ltd.
  • 16. Lonza Group Ltd.
  • 17. Midas Pharma GmbH
  • 18. ProBioGen AG
  • 19. Recipharm AB
  • 20. Rentschler Biopharma SE
  • 21. Samsung Biologics
  • 22. Thermo Fisher Scientific, Inc.
  • 23. Toyobo Co. Ltd.
  • 24. Wacker Chemie AG
  • 25. WuXi Biologics Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. BIOLOGICS CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BIOLOGICS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BIOLOGICS CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOLOGICS CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOLOGICS CONTRACT MANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT HORMONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY METABOLIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 83. MALAYSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 91. SINGAPORE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 99. TAIWAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 103. THAILAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 107. VIETNAM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 116. DENMARK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 120. EGYPT BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 124. FINLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 128. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 132. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 136. ISRAEL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 140. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 144. NETHERLANDS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 148. NIGERIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 152. NORWAY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 156. POLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 160. QATAR BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 164. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 168. SAUDI ARABIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 176. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 180. SWEDEN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 184. SWITZERLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 188. TURKEY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 197. BIOLOGICS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 198. BIOLOGICS CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023